TGF-β2-IN-1 

TGF-β2-IN-1 is a selective TGF-β2 inhibitor. TGF-β2-IN-1 exhibits potent antiproliferative effects on HCT-116, Caco-2 and HT-29 with IC₅₀ values of 6.84, 10.21, and 9.47 μM, respectively. TGF-β2-IN-1 inhibits TGF-β2 signaling in a dose-dependent manner by suppressing both receptor and cytokine expression.TGF-β2-IN-1 can be used for the study of colorectal cancer^[1].

TGF-β2-IN-1 (Compound 10k) (1.562-100 μM, 48 h) exhibits potent antiproliferative effects on HCT-116 (IC₅₀ = 6.84 μM), Caco-2 (IC₅₀ = 10.21 μM) and HT-29 (IC₅₀ = 9.47 μM)^[1].
TGF-β2-IN-1 (1.562-100 μM, 48 h) leads to progressive reductions in TGF-β2 receptor levels and TGF-β2 cytokine levels in HCT-116 cells^[1].
TGF-β2-IN-1 (50-100 μM, 48 h) does not significantly induce apoptosis or necrosis in HCT-116 cells^[1].
TGF-β2-IN-1 exhibits strong binding affinity towards the TGF-β receptor type II with an IFD XP Glide score of 11.28 kcal/mol^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

475.93

C₂₅H₂₂ClN₅O₃

COC1=CC=CC(/C=N/NC(C2=CC=CC=C2OCC3=CN(N=N3)CC4=CC(Cl)=CC=C4)=O)=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ay EN, et al. Synthesis, characterization, In vitro and In silico investigations of novel 1,2,3-triazole substituted salicylic acid phenolic hydrazones hybrids targeting TGF-β2 expression in colorectal carcinoma. Eur J Med Chem. 2025 Oct 15;296:117915.